CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen - Wikidata - wikimedia - TriplyDB

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

http://www.wikidata.org/entity/Q21195205

about

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen Prognostic and predictive biomarkers: tools in personalized oncology.Tamoxifen and CYP2D6: a contradiction of data.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Targeted therapies for ER+/HER2- metastatic breast cancer.Fine Mapping of a QTL for Fertility on BTA7 and Its Association With a CNV in the Israeli Holsteins.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence.Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study.Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer.CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival.Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.CYP2D6 genotyping in breast cancer patients by liquid chromatography-electrospray ionization mass spectrometry.CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

P2860

Q27026180-2C1A887D-62FE-4207-8C03-B84953172F3D Q33651583-1BBCC220-69D4-4E23-A195-EDB79CBDFFB0 Q34244463-9BC27945-1213-44AF-AEA8-D9475AF63659 Q34307589-185F8E26-3F4C-4559-A1F9-AB72E2257C10 Q34498728-5B18CDC9-186F-4CA7-85A2-DFE5B1D8CD11 Q34677193-367CB752-0581-469A-9619-662AE1721256 Q35009604-BF50E27A-5251-4184-B24C-5FC64A466C10 Q35020403-84C726BC-9A0E-4EAD-A451-054172DDD1B5 Q35056229-06C221F6-19FD-4986-8A33-AEAFE05FEEAB Q35058455-DA4F4B4C-03A1-49DB-9070-BD89AF5A5F0B Q35658860-B5C1C664-2F25-401D-B2F3-29A39FF751B6 Q35746682-2BACFA3C-C4DD-4A09-90CF-9DADCCBAC8B1 Q35884159-83C9E32F-7589-4A7F-889E-3813DA038211 Q36545056-6D14F15D-77CF-4A25-BBBF-C93B56C9AB19 Q36550926-B03E203A-770E-4054-8728-3E3E7BE8D3F7 Q36696957-F0F5BFA7-11B3-46A0-B479-A338A0407CDE Q36729040-D06022C8-8F84-465E-B03A-C02FAD32E4B8 Q36909858-1B416D55-D359-45C2-8E0E-74FF20E77B77 Q37065730-E04F001E-C98F-40E9-AD8E-752E6096002A Q37195587-6263CFE8-3A3F-44B3-8C47-956749495C96 Q37406272-F96D2DB6-83BA-4E67-8B52-B3A1901BA89C Q37459580-0A3376E5-133F-4044-9939-F17066335B2A Q37593514-6AA5900A-FF34-403D-B6B4-53887FC5698F Q38105253-85ED5B1D-9DEA-41E3-BF67-1C1E25B0097A Q38109822-C8B986A3-6260-46B5-A207-C5AD586A187F Q38364888-B9F193F9-E802-4E9A-B396-B35B8A98786B Q38649909-85801675-C20E-4C19-89DB-344C2AA17B73 Q39042324-C43DCB67-A217-46F2-B941-7FCCD0DE5432 Q39393568-276DD3B4-FB68-405D-B35B-F9B35BE4DA07 Q43987491-5A2C40DE-5357-4FF0-909E-423D86C95B40 Q46519655-8901E02F-BED8-433B-BA20-61F596C18DC2 Q47155427-0C6BBB9D-A088-4210-BED7-491C1AF15E76 Q48030851-989EC0A4-6108-4B1C-B855-3088A353245A Q48031154-FF94B635-6EA1-493F-B1E7-3BBA28C06D75 Q48125765-71CE35C6-86A2-4612-9391-888BB34021CE Q53116333-D7355D83-A102-4557-8493-E9E61295E91F Q54346186-F4680696-F754-4C5F-9B01-B41D38314B7F Q57561007-ACD6E525-9DD8-4BA0-A64F-376996138904

P2860

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

http://www.wikidata.org/entity/Q21195205

description

2010 nî lūn-bûn

@nan

2010 թուականին հրատարակուած գիտական յօդուած

@hyw

2010 թվականին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@ast

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en-gb

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@nl

type

label

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@ast

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en-gb

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@nl

prefLabel

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@ast

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en-gb

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@nl

P1433

Q21195205-9683388E-1983-4A0A-9973-ADACEA1FA1A3

P1476

Q21195205-0F8D544B-E269-4272-9979-B0E0D487F45A

P2093

Q21195205-07536ED0-3FC7-46C0-8279-8F837ABE0FC7

Q21195205-1242EFDE-3B15-4B2B-9178-C04A87A024DE

Q21195205-1476D32B-5E9D-4DD9-9996-B39B53E6886E

Q21195205-47316FFE-F3FA-49D2-AB69-B4AFBAD71E52

Q21195205-49BE7EA9-6BB7-480D-B3BB-22268247E416

Q21195205-8010547F-83A5-4D31-801A-A2D7AC12FDBA

Q21195205-90CC6412-967C-4E33-984D-591551367A28

Q21195205-94EF813D-5C84-4B7D-9265-30938AABE819

Q21195205-9A976917-2568-4C71-8426-C0D3CFC5BE9D

Q21195205-A4CFC955-4518-4A40-83E0-22D761FFC530

P2860

Q21195205-01020AEC-2F5E-4A78-BFF4-E81A73FF356E

Q21195205-053B835C-33CD-404A-AA5F-F4ABAA3FB4FF

Q21195205-07A6FB83-11CE-4F11-8270-36143292BFC9

Q21195205-0968B40F-9E01-4BAE-A773-16169B7E279D

Q21195205-0A69BA2F-14AA-45D8-94FD-E7DC980A1D73

Q21195205-0C808C63-7CF7-4914-A372-344259F15999

Q21195205-1467A5BE-443F-42E5-ABC8-D97DC919B654

Q21195205-18A59EDB-6157-47BF-A4C3-EEC33EDBA23A

Q21195205-1B9A3908-161C-4D21-8E53-09806837E633

Q21195205-24482EDB-55FB-437C-BC25-C1A4B15A77B8

P2888

Q21195205-A74F2FCD-408A-4C69-8AF2-A7FB79173927

P304

Q21195205-C62533E7-EBA8-4CF1-8198-EF976E762739

P31

Q21195205-36E166BC-9370-4975-9154-1E17CFC54434

P356

Q21195205-D9A75908-EA47-473E-BEC7-BFBC00F13379

P407

Q21195205-566A3F69-C8CE-40E3-9FB4-F7A7BAF6486B

P433

Q21195205-EEF63B2F-80C4-4170-BBB9-6B82F4F53D2F

P478

Q21195205-21CD3279-8B2B-43E6-8137-BEE39B38734F

P50

Q21195205-2568F29D-3DB0-4EAB-A4C6-DE3B4965B0AE

Q21195205-34E8C593-A38D-4591-8544-95E0A2CD89CC

Q21195205-6D33178A-6697-4CA2-B6D9-074E970CED71

Q21195205-D38EF91B-4B53-4471-9760-994D5B51173B

P577

Q21195205-3B51D43A-5D76-4F4A-A545-77E9D243DD50

P5875

Q21195205-381B4DD6-CA53-4F1A-8ADB-23EB08C79F0F

P6179

Q21195205-631A158A-DD4A-44AF-9B29-D7878F245D5A

P698

Q21195205-C7B2F5FC-8914-4DBA-BA88-E46E0168B046

P921

Q21195205-AD02B072-6578-4993-B976-E7EB00466368

Q21195205-F1DA9837-759E-4E61-8156-D6AC2D74058D

P932

Q21195205-EE463CA0-8070-4CAB-AF35-6CCC5FF9376C

P356

P1433

Breast Cancer Research

P1476

CYP2D6 gene variants: associat ...... reated with adjuvant tamoxifen

@en

P2093

Bolot Kalmyrzaev

http://www.w3.org/2001/XMLSchema#string

Caroline Baynes

http://www.w3.org/2001/XMLSchema#string

Craig Luccarini

http://www.w3.org/2001/XMLSchema#string

David Greenberg

http://www.w3.org/2001/XMLSchema#string

Jean E Abraham

http://www.w3.org/2001/XMLSchema#string

Kristy E Driver

http://www.w3.org/2001/XMLSchema#string

Mel J Maranian

http://www.w3.org/2001/XMLSchema#string

Mitul Shah

http://www.w3.org/2001/XMLSchema#string

Radka Platte

http://www.w3.org/2001/XMLSchema#string

Susan Ingle

http://www.w3.org/2001/XMLSchema#string

P2860

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Efficiency and power in genetic association studies

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Whole-genome patterns of common DNA variation in three human populations

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

Detection of genotyping errors by Hardy-Weinberg equilibrium testing.

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Genotype-guided tamoxifen therapy: time to pause for reflection?

P2888

P304

R64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2629

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Paul D P Pharoah

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45819945

http://www.w3.org/2001/XMLSchema#string

P6179

1024422048

http://www.w3.org/2001/XMLSchema#string

P698

20731819

http://www.w3.org/2001/XMLSchema#string

P921

P932

2949659

http://www.w3.org/2001/XMLSchema#string